• 4basebio raised £15 million to extend its cash runway to the second half of 2028.
• First-half 2026 sales orders rose 210% to £1.19 million.
• Revenue fell 78% to £262,000, while normalized gross margin increased to 72% from 64%.
• Net loss widened 14% to £8.92 million; overheads increased 1% to £9.04 million.
• Closing cash declined 46% to £14.05 million, with operating cash outflows of £8.41 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BASEBIO plc published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.